Nutramax Cosequin 11.5 Million Settlement Over Alleged False Dog Joint Health Claims

Nutramax’s Cosequin is one of the best-known over-the-counter joint supplements for dogs, marketed to pet owners concerned about aging, arthritis, and mobility issues. The California class action focused on prominent label and advertising statements promising “mobility,” “cartilage,” and “joint health support,” and on whether the core ingredients—glucosamine and chondroitin, common in both human and pet supplements—actually deliver measurable benefits in dogs. Plaintiffs pointed to peer‑reviewed veterinary research, including a VetRecord study reporting no significant improvement for dogs given Cosequin based on gait analysis, vet/owner assessments, and owner-reported outcomes. The lawsuit was filed under consumer-protection and false-advertising theories, alleging buyers paid a premium for benefits that were not adequately supported by competent scientific evidence. Without admitting wrongdoing, Nutramax agreed to an $11.5 million settlement covering California purchasers of specified Cosequin dog products from May 3, 2016 to May 6, 2022, with claims available up to $25 per unit and capped at $150 per household, and notably without requiring proof of purchase—an approach that can increase participation in low-dollar consumer cases. The significance is less about individual payouts than about how marketing for “health support” products is policed: by settling, companies may adjust claims, substantiation practices, and compliance review to reduce future litigation risk. The case fits a broader pattern of challenges to “clinically proven” or “supports joint health” messaging in the loosely regulated supplement space, where products often sit between pharmaceuticals (which require premarket proof of safety and efficacy) and conventional foods. In the U.S., pet supplements are generally treated as animal foods rather than FDA-approved drugs, and while FDA and state regulators can act against adulteration or misbranding, many disputes end up in private class actions—especially in California, where consumer statutes and advertising rules are frequently used to test whether marketing implies therapeutic effects that would require stronger substantiation. Similar suits across the supplement industry—human and pet—have pushed brands toward more carefully worded structure/function claims, clearer disclaimers, and better documentation that advertising claims are supported by reliable scientific evidence.